Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis

Autor: Jose Manuel Dodero-Anillo, Inmaculada Concepcion Lozano-Cuadra, Esmeralda Rios-Sanchez, Maria Jose Pedrosa-Martinez, Jose Carlos Ruiz-Carrascosa, Manuel Galan-Gutierrez, Jose Carlos Armario-Hita

Publikováno v: Life, Vol 12, Iss 12, p 2075 (2022)

In our clinical experience, more than half of patients do not present a complete response to biologic drugs, or drug loses its efficacy over time. Plasma determinations of drug and anti-drug antibodies levels are an objective tool for optimisation in

Externí odkaz: https://doaj.org/article/5b3adc15830e447fbb271e318dc1c61a

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

Autor: Angela Ayen-Rodríguez, José-Juan Pereyra-Rodríguez, Francisco J. Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, Manuel Galán-Gutiérrez, Samuel Vilar-Palomo, Jose Carlos Armario-Hita, Ricardo Ruiz-Villaverde

Publikováno v: Life, Vol 12, Iss 8, p 1159 (2022)

Introduction: Atopic dermatitis (AD) is a genetically based chronic inflammatory dermatosis associated with multiple triggers and complex pathophysiological mechanisms. Nowadays, an authentic therapeutic revolution is taking place with the incorporat

Externí odkaz: https://doaj.org/article/9764257d286944cd944aff1356ec20e4

Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

Autor: Ricardo Ruiz‐Villaverde, Lourdes Rodriguez‐Fernandez‐Freire, Jose Carlos Armario‐Hita, Amalia Pérez‐Gil, Fiorella Vasquez Chinchay, Manuel Galán‐Gutiérrez

The IL23/Th17 axis plays a strategic role in psoriasis (PSO). Guselkumab (GUS) is a selective inhibitor of the IL23p19 subunit. Its introduction has managed to increase the levels of efficacy, safety and survival in PSO. In real clinical practice, pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf76cbc68be58ff598376215c2505b23
https://hdl.handle.net/10668/19939

Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: Where Are We Going?

Autor: Ricardo Ruiz-Villaverde, Marta Cebolla-Verdugo, Alvaro Prados-Carmona, José Juan Pereyra Rodríguez, José Carlos Armario-Hita

Publikováno v: Life, Vol 14, Iss 10, p 1236 (2024)

Dermatology is one of the oldest specialties and yet one of the most innovative and constantly evolving ones, too [...]

Externí odkaz: https://doaj.org/article/b397f995e5f047de86e163f5d49fea74

Omalizumab: what benefits should we expect?

Autor: Ana Giménez-Arnau, Jose Carlos Armario Hita, Moises Labrador-Horrillo, Juan Francisco Silvestre Salvador, Manel Velasco

Publikováno v: EUROPEAN JOURNAL OF DERMATOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background: Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy. Objectives: To investigate the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6964654e5a159236e20eb7b66578b6d
https://pubmed.ncbi.nlm.nih.gov/27210073